Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
Reibnegger, G; Fuchs, D; Fuith, LC; Hausen, A; Werner, ER; Werner-Felmayer, G; Wachter, H.
Neopterin as a marker for activated cell-mediated immunity: application in malignant disease.
Cancer Detect Prev. 1991; 15(6):483-490
Web of Science
PubMed
Google Scholar
- Führende Autor*innen der Med Uni Graz
- Reibnegger Gilbert
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Abstract:
- A review is presented on studies concerning neopterin determination in patients with malignant neoplastic diseases. Neopterin is produced chiefly by human macrophages through their activation by T-cell-derived interferon gamma. In vivo, determinationof neopterin in various body fluids provides a convenient way to monitor early events that are involved in cell-mediated immune responses. In malignant neoplasia, elevation of neopterin concentrations in body fluids depends on tumor type. Within a given type of tumor, more advanced stages are generally associated with higher levels than early disease. In a variety of different tumor types and sites, a significantly poorer prognosis was associated with high pretherapeutic neopterin concentrations. This predictive value is independent of several possible confounders such as stage or therapy. During follow-up malignant disease, neopterin elevations may predict deterioration of the clinical status of the patients and thereby provide a valuable additional marker for monitoring such patients. Possible immunobiological implications of the results are discussed.
- Find related publications in this database (using NLM MeSH Indexing)
- Biopterin - analogs and derivatives
- Female - analogs and derivatives
- Humans - analogs and derivatives
- Immunity, Cellular - immunology
- Male - immunology
- Neoplasms - chemistry
- Neopterin - chemistry
- Tumor Markers, Biological - analysis
- Find related publications in this database (Keywords)
- NEOPTERIN
- CELL-MEDIATED IMMUNITY
- CANCER
- PROGNOSIS
- FOLLOW-UP